Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
34 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-24 |
Cash Flow (TTM) (Millions $) |
-101 |
Capital Exp. (TTM) (Millions $) |
1 |
Prevail Therapeutics Inc
Prevail Therapeutics Inc is a biotechnology company that focuses on developing novel gene therapies for patients with neurodegenerative diseases. The company is dedicated to discovering and advancing breakthrough treatments for diseases such as Parkinson's disease, frontotemporal dementia, and Alzheimer's disease.
Prevail Therapeutics utilizes a proprietary gene therapy platform that enables the precise targeting and delivery of therapeutic genes to the affected regions of the brain. This approach aims to restore the normal functioning of cells and slow down the progression of these debilitating diseases.
The company has a pipeline of product candidates at various stages of development, with the goal of providing patients with effective and long-lasting treatments. Prevail Therapeutics is committed to leveraging scientific advancements and collaborating with industry partners to bring potentially transformative therapies to market and improve the lives of patients suffering from neurodegenerative diseases.
Company Address: 430 East 29th Street New York 10016 NY
Company Phone Number: 336-9310 Stock Exchange / Ticker: NASDAQ PRVL
|